Program
Vortioxetine
Also written as “Vortioxetine (Lu AA21004)”, “Lu AA21004” and “Vortioxetine 10 mg/day”.
Its studies are mostly in Depressive Disorder, Major · Generalized Anxiety Disorder · Depression · Anxiety Disorders · Attention Deficit Disorder with Hyperactivity, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| H. Lundbeck | 350 open or running | phase 4since Jan 5, 2015 | Jan 8, 2008 | none ahead |
| Takeda | 251 open or running | phase 4since Feb 20, 2015 | May 2, 2008 | Sep 30, 2029phase 3 · NCT07204314 |
| Scotmann Pharmaceuticals | 10 open or running | phase 3since Oct 26, 2021 | Oct 26, 2021 | none ahead |
| Seasons Biotechnology (Taizhou) | 10 open or running | phase 1since Jun 6, 2022 | Jun 6, 2022 | none ahead |
Also a collaborator on its studies: icon-plc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since May 2, 2008.
- Nov 21, 2016Phase 4 study in Depressive Disorder, MajorTakeda · NCT02972632 · 123 enrolled · United States
- Mar 10, 2017Phase 3 study in Depressive Disorder, MajorH. Lundbeck · NCT03108625 · 94 enrolled · Bulgaria, Estonia, France and more
- Feb 13, 2018Phase 1 study in Healthy Adult ParticipantsTakeda · NCT03437564 · 28 enrolled · Japan
- Dec 5, 2018Phase 2 study in Depressive Disorder, MajorH. Lundbeck · NCT03766867 · 80 enrolled · Bulgaria, Estonia, Latvia
- Feb 7, 2019Phase 4 study in Depressive Disorder, MajorH. Lundbeck · NCT03835715 · 150 enrolled · France, Italy, Lithuania and more
- Mar 19, 2019Phase 1 study in HealthyH. Lundbeck · NCT03884491 · 16 enrolled · United Kingdom
- Jan 6, 2020Phase 4 study in Anxiety DisordersH. Lundbeck · NCT04220996 · 100 enrolled · Estonia, France, Italy and more
- Feb 26, 2020Phase 4 study in Depressive Disorder, MajorH. Lundbeck · NCT04288895 · 400 enrolled · India
- Mar 2, 2020Phase 4 study in Depressive Disorder, MajorH. Lundbeck · NCT04294654 · 82 enrolled · Estonia, France, Italy and more
- Jun 23, 2020Phase 4 study in Depressive Disorder, MajorH. Lundbeck · NCT04448431 · 605 enrolled · Argentina, Belgium, Bulgaria and more
- Aug 16, 2021Phase 3 study in DepressionH. Lundbeck · NCT05014919 · 35 enrolled · United States, Colombia, Latvia and more
- Oct 26, 2021Scotmann Pharmaceuticals's first study: phase 3 study in Depressive Disorder, MajorNew to Scotmann PharmaceuticalsScotmann Pharmaceuticals · NCT05104918 · 500 enrolled
- Jun 6, 2022Seasons Biotechnology (Taizhou)'s first study: phase 1 study in Depressive Disorder, MajorNew to Seasons Biotechnology (Taizhou)Seasons Biotechnology (Taizhou) · NCT05417087 · 48 enrolled · India
- Sep 30, 2025Phase 3 study in Depressive Disorder, MajorTakeda · NCT07204314 · 180 planned · Japan
Ahead
- Sep 30, 2029Primary completion: phase 3 study in Depressive Disorder, MajorTakeda · NCT07204314
TargetBeta
“A hydrobromide salt form of vortioxetine, a serotonin (5-HT) modulator and stimulator (SMS), with antidepressant activity”NCIt, by rule
“Serotonin 1a (5-HT1a) receptor agonist; Serotonin transporter inhibitor; Serotonin 3a (5-HT3a) receptor antagonist”ChEMBL 37, by rule
Studies
The newest 60 of 62 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07204314Depressive Disorder, Major · Japan | 3 | Recruiting | Takeda | Sep 30, 2029 | 180 |
| NCT05417087Depressive Disorder, Major · India | 1 | Completed | Seasons Biotechnology (Taizhou) | Sep 2, 2022 | 48 |
| NCT05104918Depressive Disorder, Major | 3 | UNKNOWN | Scotmann Pharmaceuticals | Apr 2022 | 500 |
| NCT05014919Depression · United States, Colombia, Latvia and more | 3 | Terminated | H. Lundbeck | Mar 31, 2022 | 35 |
| NCT04448431Depressive Disorder, Major · Argentina, Belgium, Bulgaria and more | 4 | Completed | H. Lundbeck | Jan 6, 2022 | 605 |
| NCT04294654Depressive Disorder, Major · Estonia, France, Italy and more | 4 | Completed | H. Lundbeck | Jul 6, 2022 | 82 |
| NCT04288895Depressive Disorder, Major · India | 4 | Completed | H. Lundbeck | Feb 11, 2022 | 400 |
| NCT04220996Anxiety Disorders · Estonia, France, Italy and more | 4 | Completed | H. Lundbeck | Mar 9, 2021 | 100 |
| NCT03884491Healthy · United Kingdom | 1 | Completed | H. Lundbeck | Jun 25, 2019 | 16 |
| NCT03835715Depressive Disorder, Major · France, Italy, Lithuania and more | 4 | Completed | H. Lundbeck | Feb 21, 2020 | 150 |
| NCT03766867Depressive Disorder, Major · Bulgaria, Estonia, Latvia | 2 | Completed | H. Lundbeck | Jul 31, 2019 | 80 |
| NCT03437564Healthy Adult Participants · Japan | 1 | Completed | Takeda | Apr 13, 2018 | 28 |
| NCT03108625Depressive Disorder, Major · Bulgaria, Estonia, France and more | 3 | Completed | H. Lundbeck | Apr 16, 2020 | 94 |
| NCT02972632Depressive Disorder, Major · United States | 4 | Completed | Takeda | Feb 6, 2018 | 123 |
| NCT02932904Healthy Volunteers · United States | 4 | Completed | Takeda | May 31, 2017 | 361 |
| NCT02919501Depressive Disorder, Major · Estonia, Finland | 2 | Completed | H. Lundbeck | Apr 27, 2017 | 55 |
| NCT02871297Depressive Disorder, Major · United States, Bulgaria, Canada and more | 3 | Terminated | H. Lundbeck | Mar 25, 2022 | 662 |
| NCT02709746Depressive Disorder, Major · United States, Bulgaria, Canada and more | 3 | Completed | H. Lundbeck | Jul 2, 2019 | 784 |
| NCT02709655Depressive Disorder, Major · United States, Bulgaria, Canada and more | 3 | Completed | H. Lundbeck | Jan 21, 2022 | 683 |
| NCT02389816Depressive Disorder, Major · Japan | 3 | Completed | Takeda | Mar 16, 2018 | 493 |
| NCT02386488Pharmacokinetics · China | 1 | Completed | H. Lundbeck | May 2015 | 64 |
| NCT02371980Depressive Disorder, Major · United States | 4 | Completed | Takeda | Mar 1, 2019 | 1,106 |
| NCT02332954Depressive Disorder, Major · Canada | 4 | Completed | H. Lundbeck | Jul 6, 2017 | 226 |
| NCT02327013Attention Deficit Disorder with Hyperactivity · United States | 2 | Completed | H. Lundbeck | Sep 2016 | 227 |
| NCT02279966Depressive Disorder, Major · Estonia, Finland, Germany and more | 3 | Completed | H. Lundbeck | Feb 2016 | 152 |
| NCT02279953Depressive Disorder, Major · Estonia, Finland, Germany and more | 3 | Completed | H. Lundbeck | Apr 2016 | 151 |
| NCT02272517Depressive Disorder, Major · Finland, Germany, Serbia and more | 3 | Completed | H. Lundbeck | Mar 2016 | 101 |
| NCT02170220Severe Hepatic Impairment · United States | 1 | Completed | Takeda | Nov 2014 | 12 |
| NCT02072278Healthy Men · France | 1 | Completed | H. Lundbeck | Nov 2014 | 32 |
| NCT01676571Healthy · China | 1 | Completed | H. Lundbeck | Nov 2012 | 16 |
| NCT01607125Depression · United Kingdom | 1 | Completed | H. Lundbeck | Sep 2013 | 96 |
| NCT01571453Depressive Disorder, Major | 3 | Completed | H. Lundbeck | Oct 2013 | 437 |
| NCT01564862Depressive Disorder, Major · United States, Bulgaria, Finland and more | 2 | Completed | Takeda | Feb 2014 | 602 |
| NCT01488071Depressive Disorder, Major | 3 | Completed | H. Lundbeck | Dec 2012 | 495 |
| NCT01491035Depressive Disorder · United States, Germany | 2 | Completed | H. Lundbeck | Dec 2014 | 48 |
| NCT01422213Depressive Disorder, Major | 3 | Completed | H. Lundbeck | May 2013 | 598 |
| NCT01395147Depressive Disorder, Major · Japan | 3 | Completed | Takeda | May 2013 | 119 |
| NCT01364649Sexual Dysfunction, Physiological · United States, Canada | 3 | Completed | Takeda | Dec 2013 | 447 |
| NCT01355081Depressive Disorder, Major · Japan | 3 | Completed | Takeda | Dec 2012 | 366 |
| NCT01323478Depressive Disorder, Major | 3 | Completed | H. Lundbeck | Sep 2012 | 71 |
| NCT01299805Healthy · United States | 1 | Completed | Takeda | Jun 2011 | 17 |
| NCT01255787Depressive Disorder, Major · Croatia, Finland, Germany and more | 3 | Completed | Takeda | Mar 2012 | 600 |
| NCT01179516Depressive Disorder, Major · United States | 3 | Completed | Takeda | May 2012 | 469 |
| NCT01163266Depressive Disorder, Major · United States | 3 | Completed | Takeda | Jan 2012 | 462 |
| NCT01153009Depressive Disorder, Major · United States | 3 | Completed | Takeda | Mar 2012 | 614 |
| NCT01152996Depressive Disorder, Major | 3 | Completed | Takeda | May 2013 | 1,075 |
| NCT01140906Depressive Disorder, Major | 3 | Completed | H. Lundbeck | Sep 2011 | 607 |
| NCT00839423Depressive Disorder, Major | 2 | Completed | H. Lundbeck | Aug 2007 | 426 |
| NCT00811252Depressive Disorder, Major | 3 | Completed | H. Lundbeck | Feb 2010 | 453 |
| NCT00788034Generalized Anxiety Disorder · Argentina, Chile, Colombia and more | 3 | Completed | H. Lundbeck | Jun 2010 | 459 |
| NCT00761306Depressive Disorder, Major | 2 | Completed | H. Lundbeck | Sep 2008 | 74 |
| NCT00744627Generalized Anxiety Disorder · Estonia, Germany, Latvia and more | 3 | Completed | Takeda | Jul 2009 | 301 |
| NCT00735709Depressive Disorder, Major · Australia, Czech Republic, France and more | 3 | Completed | Takeda | Jul 2009 | 560 |
| NCT00734071Generalized Anxiety Disorder · United States | 3 | Completed | Takeda | Jan 2009 | 304 |
| NCT00731120Generalized Anxiety Disorder · United States | 3 | Completed | Takeda | Jan 2009 | 457 |
| NCT00730691Generalized Anxiety Disorder · United States | 3 | Completed | Takeda | Feb 2009 | 781 |
| NCT00707980Depressive Disorder, Major · United States, Australia, Croatia and more | 3 | Completed | Takeda | Jul 2010 | 836 |
| NCT00694304Depressive Disorder, Major | 3 | Completed | H. Lundbeck | Mar 2010 | 535 |
| NCT00672958Depressive Disorder, Major · United States, Canada, Mexico | 3 | Completed | Takeda | Nov 2008 | 600 |
| NCT00672620Depressive Disorder, Major · United States | 3 | Completed | Takeda | Nov 2008 | 611 |
How it is read
Names in the registry
- “Vortioxetine”, 35 entries
- “Vortioxetine (Lu AA21004)”, 15 entries
- “Lu AA21004”, 3 entries
- “Vortioxetine 10 mg/day”, 2 entries
- “Vortioxetine 20 mg/day”, 2 entries
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 43 studies
- Generalized Anxiety Disorder, 5 studies
- Depression, 2 studies
- Anxiety Disorders, 1 study
- Attention Deficit Disorder with Hyperactivity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.